Vol 2011, No 10 (2011)

Table of Contents

Research & Development

BMS/Ambrx Deal Highlights Big Pharma’s Growing Interest in Protein Drug Engineering Abstract
Heather Cartwright
Lundbeck Invests US$16 M in Proximagen in Strategic CNS Collaboration Abstract
Heather Cartwright
Galapagos and Servier Form Multiyear Cancer Therapeutics Partnership Abstract
Heather Cartwright

Licensing

Merck & Co. Out-Licenses Gene Therapy Portfolio to Finnish Start-Up FKD Therapies Abstract
Heather Cartwright
BMS Gains Expanded Territorial Rights to Anti-PD-1 Antibody from Ono Pharmaceutical Abstract
Heather Cartwright
ViroPharma to Develop Intellect Neurosciences’ OX1 for Friedreich’s Ataxia Abstract
Heather Cartwright
AstraZeneca’s MedImmune In-Licenses Pfizer’s Tremelimumab Abstract
Heather Cartwright
Gilead Licenses Boehringer Ingelheim’s NCINI Inhibitors for HIV Abstract
Heather Cartwright
Pfizer Out-Licenses its Pan-HER Inhibitor Neratinib to Puma Biotechnology Abstract
Heather Cartwright

Mergers & Acquisitions

Biotie Agrees to Acquire Newron to Strengthen its Late-Stage CNS Pipeline Abstract
Heather Cartwright
Santen Pharmaceutical Strengthens its Ophthalmology Portfolio with Novagali Pharma Acquisition Abstract
Heather Cartwright

Cartoons

Whales Abstract jpg
Clive Goddard


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.